2016-Sustainable Industrial Processing Summit
SIPS 2016 Volume 10: Battery, Recycling, Environmental, Mining
| Editors: | Kongoli F, Kumar V, Aifantis K, Pagnanelli F |
| Publisher: | Flogen Star OUTREACH |
| Publication Year: | 2016 |
| Pages: | 220 pages |
| ISBN: | 978-1-987820-54-6 |
| ISSN: | 2291-1227 (Metals and Materials Processing in a Clean Environment Series) |
CD shopping page
Evaluation of a Newly Synthesized Ligand as Peptide Radionuclide Therapy on Neuro-Endocrine Tumor
Sunju Choi1;1KAERI, Daejon, Korea (Republic of [South] Korea);
Type of Paper: Regular
Id Paper: 426
Topic: 10
Abstract:
Among the modalities in the treatment of malignant tumor, chemotherapy is the 1st line of the tumor therapy due to its efficient and effective way, but a lack of specificity often causes an indiscriminate toxicity to normal cells. There have been many attempts to reduce its unwanted toxicities. Small molecules like monoclonal antibodies and receptor targeting agents get the attention for the new modalities. Recently radiopeptide therapies have got the world attraction for the tumor targeting modalities due to its beneficial effect on less side effect compared to cytotoxic chemotherapies including pain palliation. In nuclear medicine, 177Lu-DOTATATE is known to be a new modality as an effective one invented so far in treating neuroendocrine tumor (NET) and it has been in clinical trials in globally due to many beneficial effects. The study still should have been extended to overcome its less effective in the large solid tumor. To improve the effectiveness of radiopeptide therapy, potent small molecules were selected to target the tumor site selectively and its labeling with a radioisotope of emitting high-energy was confirmed through present study. Also, the present study was a focus to increase a biological half-life of radio somatostatin peptide which targets the somatostatin receptor by altering the bifunctional chelator (BFCA) and at the same time introducing moiety to increase its lipophilicity. The present study will introduce a new concept of a radio-peptide therapy in the neuro-endocrine tumor.